Workflow
b
icon
搜索文档
Allbirds Announces New Distributor Agreements Across the Eurasian Corridor
Globenewswire· 2025-07-10 04:05
文章核心观点 - Allbirds公司签署三份欧亚地区分销协议以实现海外市场长期可扩展增长,至此已与全球16家公司达成分销合作 [1] 公司战略与成果 - Allbirds向国际分销模式转型战略成功,过去18个月与世界级分销商合作拓展品牌影响力并实现盈利运营 [2] 合作方情况 Beosport - 东南欧领先的高端运动服饰、鞋类和生活方式品牌零售及分销公司,1996年成立于塞尔维亚贝尔格莱德 [2] - 拥有广泛零售网络和大量批发合作伙伴,以客户为中心且市场知识丰富,是国际品牌拓展当地业务的可靠伙伴 [2] 911 Fashion - 2001年由Uri Reiss创立的时尚和生活方式分销公司,获GOTS认证 [3] - 拥有精心挑选的国际品牌组合,注重品牌的可持续性和社会责任感 [3] Tradist Distribution - 土耳其、东欧和中亚地区领先的高端生活方式、鞋类和包袋品牌分销商,总部位于伊斯坦布尔 [4] - 专注品牌建设、零售扩张和全渠道增长,为全球品牌提供端到端分销、电商运营等服务 [4] 合作安排 - Beosport将于2026年1月起成为巴尔干地区Allbirds独家分销商 [5] - 911 Fashion将于2025年10月起成为以色列Allbirds独家分销商 [5] - Tradist Distribution于2025年7月起成为土耳其和中亚地区Allbirds独家分销商 [5] Allbirds公司简介 - 2015年成立的全球现代生活方式鞋类品牌,致力于以更好方式制造产品 [6] - 首款产品为标志性的Wool Runner,现有产品注重舒适,采用美利奴羊毛等天然材料 [6]
MingZhu Logistics Plans to Partner with Muamau Mall to Jointly Explore the Vietnam and the U.S. Markets
Globenewswire· 2025-07-10 04:05
SHENZHEN, July 09, 2025 (GLOBE NEWSWIRE) -- MingZhu Logistics Holdings Limited (“MingZhu” or the “Company”) (Nasdaq: YGMZ), an elite provider of logistics and transportation services to businesses, today announced that on July 7, 2025, it executed a non-binding memorandum of understanding (“MOU”) with ENEXTREND.VN COMPANY LIMITED (“Enextrend”), a Vietnam registered company which owns the emerging cross-border e-commerce platform – Muamau Mall. The strategic partners plan to leverage their respective expert ...
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance
Globenewswire· 2025-07-10 04:05
文章核心观点 临床阶段生物制药公司Inventiva宣布领导层过渡,任命Jason Campagna为研发总裁兼首席医疗官、Martine Zimmermann为监管事务与质量保证执行副总裁,凸显公司对长期增长和卓越运营的承诺,NATiV3试验预计2026年下半年出 topline结果 [1][6] 公司领导层变动 - Jason Campagna加入公司高管团队,拥有MASH领域丰富专业知识,接替Pierre Broqua和Michael Cooreman的职位,此前担任Q32 Bio首席医疗官等职 [1][2] - Martine Zimmermann加入公司高管团队,最近任职于Ipsen,成功带领团队获得两款肝病药物监管批准,此前在Alexion Pharma任职 [1][3] - Pierre Broqua将过渡到科学顾问的咨询角色,Michael Cooreman将离开公司 [2] 各方表态 - 公司首席执行官Frederic Cren表示二人带来卓越领导力和经验,感谢Michael的贡献 [4] - Jason Campagna称公司有坚实基础,期待推进lanifibranor监管提交,认为2b期NATIVE试验结果令人兴奋 [4] - Martine Zimmermann表示很高兴在关键监管阶段担任领导角色,期待运用经验支持lanifibranor获批 [4] 公司概况 - 公司是临床阶段生物制药公司,专注MASH等疾病口服小分子疗法研发,正在进行lanifibranor的NATiV3 3期临床试验 [5] - 公司在泛欧证券交易所巴黎市场B板块和美国纳斯达克全球市场上市 [6]
Duolingo to Announce Second Quarter 2025 Results on Wednesday August 6, 2025
Globenewswire· 2025-07-10 04:05
PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Duolingo, Inc. (Nasdaq: DUOL), the world's leading mobile learning platform, will announce its results for the second quarter ending June 30, 2025, following the close of the U.S. market on Wednesday, August 6, 2025. The Company will host a video webcast at 5:30 p.m. ET on that day. The live video webcast will be accessible to the public through Duolingo’s Investor Relations website at https://investors.duolingo.com. A replay of the event will be available two h ...
Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results
Seeking Alpha· 2025-07-10 04:04
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...
After a 246% Rally, Is Navitas Semiconductor a Buy or a Hold in 2025?
ZACKS· 2025-07-10 04:01
Key Takeaways NVTS stock jumped 246% in three months, far outpacing sector benchmarks and semiconductor peers. Investor optimism is driven by GaN and SiC innovations, EV wins and AI data center design traction. Despite growth prospects, NVTS faces soft revenues, margin pressure and trades at 15.5x forward P/S.Navitas Semiconductor (NVTS) has delivered a standout performance in 2025, with its stock skyrocketing 246% over the past three months, far outpacing the broader Electronics - Semiconductors industry ...
Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine
Globenewswire· 2025-07-10 04:01
文章核心观点 Tonix公司公布TNX - 102 SL治疗纤维肌痛的3期RESILIENT试验完整结果,显示其在减轻疼痛方面有显著效果且耐受性良好,若获批将是15多年来首个治疗纤维肌痛的新药,公司已提交新药申请,FDA目标审批日期为2025年8月15日 [1][2] 分组1:TNX - 102 SL治疗纤维肌痛试验结果 - TNX - 102 SL在减轻纤维肌痛疼痛的主要终点上较安慰剂有统计学显著改善,且耐受性良好,结果与之前的RELIEF 3期试验一致 [1] - RESILIENT试验是双盲、随机、安慰剂对照试验,招募457名成年纤维肌痛患者,TNX - 102 SL治疗使每日疼痛数字评分量表上的最小二乘均值降低1.8分,安慰剂组降低1.2分,在所有六个预先指定的关键次要终点上也有显著改善 [2][7] - TNX - 102 SL最常见的治疗突发不良事件为口腔刺痛/麻木和苦味或明显余味,通常轻微、短暂且自限,无药物相关严重不良事件或死亡报告 [3] 分组2:纤维肌痛疾病信息 - 纤维肌痛是中枢神经系统内感觉和疼痛信号放大导致的慢性疼痛疾病,美国约600 - 1200万成年人受影响,约90%为女性 [4] - 症状包括慢性广泛疼痛、睡眠质量差、疲劳、晨僵等,患者日常活动受影响,生活质量受损,医生和患者对现有产品普遍不满 [4] 分组3:TNX - 102 SL产品信息 - TNX - 102 SL是盐酸环苯扎林的专利舌下片剂配方,可快速经粘膜吸收,减少长效活性代谢物去甲环苯扎林的产生 [5] - 作为多功能药物,正在开发用于治疗纤维肌痛、急性应激反应/急性应激障碍、长新冠、酒精使用障碍和阿尔茨海默病激越等 [5] - 相关专利预计在新药申请获批后,为TNX - 102 SL提供至2034/2035年的美国市场独占权 [6] 分组4:Tonix公司信息 - Tonix是专注于疼痛管理疗法和公共卫生挑战疫苗的综合生物技术公司,开发重点是中枢神经系统疾病 [8] - 公司优先推进TNX - 102 SL治疗纤维肌痛,已基于两项有统计学意义的3期试验提交新药申请,FDA授予快速通道指定 [8] - 公司免疫学开发组合包括用于解决器官移植排斥、自身免疫和癌症的生物制剂,传染病组合包括用于猴痘和天花的疫苗TNX - 801等 [8] - 公司商业子公司Tonix Medicines销售用于治疗成人急性偏头痛的Zembrace SymTouch和Tosymra [8] 分组5:Zembrace SymTouch和Tosymra药品信息 - Zembrace SymTouch注射剂和Tosymra鼻喷雾剂是处方药,用于治疗成人有或无先兆的急性偏头痛,不能预防偏头痛,安全性和有效性在18岁以下儿童中未知 [12][13] - 药品可能导致严重副作用,包括心脏病发作等,有心脏病风险因素者需经心脏检查无问题才可使用,使用前需告知医生所有医疗状况和用药情况 [14][15] - 常见副作用包括注射部位疼痛和发红、手指或脚趾刺痛或麻木等,还可能导致一些严重但不常见的副作用,如血清素综合征等 [16][20]
TASKUS BUYOUT INVESTIGATION NOTICE: Kaskela Law LLC Announces Investigation into Proposed Buyout of TaskUs, Inc. (NASDAQ: TASK) Shareholders - Does $16.50 Per Share Represent Sufficient Payment for TASK Shares?
Prnewswire· 2025-07-10 03:19
PHILADELPHIA, July 9, 2025 /PRNewswire/ -- Kaskela Law LLC announces that it has launched an investigation into the fairness of the recently announced buyout of TaskUs, Inc. (Nasdaq: TASK) shareholders to determine whether the proposed buyout price of $16.50 per share undervalues the company's shares.Click here for additional information about this investigation: https://kaskelalaw.com/case/taskus-buyout/On May 9, 2025, TaskUs announced that it had agreed to be acquired by the company's co-founders and Blac ...
Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch
Seeking Alpha· 2025-07-10 03:09
If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ), the Boston-based pharma, have been gathering some momentum since the company shared longer-term data from its studies of its Sickle Cell Disease/transf ...
Johnson & Johnson's Outlook Clouded By $2 Billion Headwind
Benzinga· 2025-07-10 02:38
核心观点 - 强生公司将于7月16日公布第二季度财报 分析师预计调整后每股收益为2 68美元 营收为228 5亿美元[1] - 投资者关注重点包括2025年业绩指引更新 关税和生物类似药影响 以及产品管线进展[1][3] - 美国银行小幅上调2025年第二季度营收和每股收益预测1% 全年营收预测上调1% 每股收益预测上调2% 主要受汇率变动驱动[4] 财务预测 - 美国银行维持中性评级 目标价61美元 认为股票估值合理 因长期每股收益增长平均且市盈率高于行业水平[5] - 强生预计2025年将面临20亿美元净不利因素 分布在全年 影响产品包括Stelara Tremfya Invega系列等 但Xarelto预计受益[6] - 首席财务官将2025年关税影响预估从4亿美元下调至2亿美元 主要影响下半年 未考虑潜在232条款关税[7] 行业动态 - 联邦法院驳回强生修改其参与340B药品定价计划的请求 该计划要求制药商以折扣价向低收入和农村医疗机构提供药品[7][8] - 强生股价周三下跌0 18%至155 51美元[8]